GSK to buy US cancer treatment firm Nuvalent for $10.6bn | TheBriefWire
GSK to buy US cancer treatment firm Nuvalent for $10.6bn
Published 9 June 2026 Ā· health
British drugmakerās new chief executive Luke Miels announces one of its biggest deals Business live ā latest updates GSKās new boss Luke Miels has struck
British drugmakerās new chief executive Luke Miels announces one of its biggest deals Business live ā latest updates GSKās new boss Luke Miels has struck one of the British drugmakerās biggest deals, announcing the $10.6bn (Ā£7.9bn) acquisition of a US cancer specialist with two-late stage medications. The FTSE 100 company is boosting its oncology portfolio by agreeing to buy Nuvalent, a Boston-based company that develops cancer drugs, including three for lung cancer. Continue reading...
Published: June 9, 2026 ā¢ 12:58 PM IST Ā· Updated: June 9, 2026 ā¢ 1:39 PM ISTBy TheBriefWire Editorial Team
Key points
British drugmakerās new chief executive Luke Miels announces one of its biggest deals Business live ā latest updates GSKās new boss Luke Miels has struck one of the British drugmakerās biggest deals, announcing the $10.6bn (Ā£7.9bn) acquisition of a US cancer specialist with two-late stage medications.
The FTSE 100 company is boosting its oncology portfolio by agreeing to buy Nuvalent, a Boston-based company that develops cancer drugs, including three for lung cancer.
The BriefWire